CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that it will effect a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-5, effective at 5:00 p.m. ET on August 28, 2026.

CalciMedica’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis commencing upon market open on August 31, 2026 under CalciMedica’s existing trading symbol "CALC" with a new CUSIP number, 38942Q301. The reverse stock split was approved by CalciMedica’s stockholders at CalciMedica’s Annual Meeting of Stockholders held on August 19, 2026, with the final ratio subsequently determined by CalciMedica’s Board of Directors. The reverse stock split is intended to bring CalciMedica into compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.